Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
Reason given: The study was closed prematurely due to low enrollment.
Key facts
- Where
- Oxford, United KingdomSee the site
- Phase
- Phase 2
Where in United Kingdom
- Genesis CareOxford, United KingdomNo longer taking part
Trial details
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- NCT04984343
- Record updated
- 23 April 2026
- Original description
The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.Read full original descriptionShow less
Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.
Inclusion: Men aged >=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines; ECOG 0 - 1; IPSS < 18; Ability to receive MRI-guided radiotherapy; Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire; Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.
Exclusion: Prior history of receiving pelvic radiotherapy; TURP < 8 weeks prior to radiotherapy; Patient with history of inflammatory bowel disease; History of bladder neck or urethral stricture; Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA PET scan; MRI Prostate Volume > 80 cc; MRI Stage > T3a; Unilateral or bilateral hip replacements.